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4-Hydroxy-2-nonenal (HNE) is one of the most studied products of phospholipid peroxidation, owing to
its reactivity and cytotoxicity. It can be formed by several radical-dependent oxidative routes involving
the formation of hydroperoxides, alkoxyl radicals, epoxides, and fatty acyl cross-linking reactions.
Cleavage of the oxidized fatty acyl chain results in formation of HNE from the methyl end, and 9-oxo-
nonanoic acid from the carboxylate or esteriﬁed end of the chain, although many other products are
also possible. HNE can be metabolized in tissues by a variety of pathways, leading to detoxiﬁcation and
excretion. HNE-adducts to proteins have been detected in inﬂammatory situations such as athero-
sclerotic lesions using polyclonal and monoclonal antibodies, which have also been applied in ELISAs
and western blotting. However, in order to identify the proteins modiﬁed and the exact sites and nature
of the modiﬁcations, mass spectrometry approaches are required. Combinations of enrichment
strategies with targetted mass spectrometry routines such as neutral loss scanning are now facilitating
detection of HNE-modiﬁed proteins in complex biological samples. This is important for characterizing
the interactions of HNE with redox sensitive cell signalling proteins and understanding how it may
modulate their activities either physiologically or in disease.
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Open access under CC BY-NC-NDiscovery and importance of 4-hydroxy-2-nonenal
Phospholipid peroxidation generates a large number of diverse
products, including breakdown products resulting from cleavage
of the oxidized fatty acyl chain. One of the most studied products,
which results from oxidation of phospholipids containing o-6
polyunsaturated fatty acyl chains, is 4-hydroxy-trans-2-nonenal
(HNE). This compound falls into the class of a, b-unsaturated
aldehydes, which are bi-reactive compounds able to undergo
electrophilic reactions such as Michael addition, as well as Schiff
base formation. The compound now known to be HNE was ﬁrst
detected and characterized as a 4-hydroxyalkenal byD license.
C.M. Spickett / Redox Biology 1 (2013) 145–152146Schauenstein et al. in the early 1960 s [1], although unfortunately
it was initially mis-identiﬁed as 4-hydroxyoctenal, based on
inconclusive microanalysis data that suggested the presence of
between eight and nine carbons. At the time there was little
interest in these hydroxyalkenals, which were thought to be
uninteresting by-products of lipid autoxidation during rancidiﬁ-
cation, despite the fact that they showed potential tumoristatic
activity and selective toxicity in tumour cell lines compared to
non-cancerous cells [1,2]. Subsequently the structure of HNE
compound was correctly characterized, and it was found to occur
in rat liver subjected to oxidative damage by carbon tetrachlor-
ide [3]. The hydroxyalkenals were found to be the major low
molecular weight products of biological lipid peroxidation and of
these, HNE was found to be the most cytotoxic, with biological
effects in the low micromolar range [4], as well as the most
abundant following oxidation of arachidonic acid [5]. The ensuing
collaboration between the Austrian and Italian research groups
marked a turning point in this research [6]; subsequently scien-
tiﬁc interest in this molecule expanded exponentially to address
all aspects of its biochemistry and roles in pathophysiology.Mechanisms of 4-hydroxy-2-nonenal generation
For many years, the chemical reaction mechanisms by which
HNE or analogous 4-hydroxyalkenals could be formed were not
well understood. Early experiments demonstrated that o-6 poly-
unsaturated fatty acyl chains were required for HNE formation,
whereas oxidation of o-3 polyunsaturated chains gave rise to its
analogue 4-hydroxyhexenal, indicating that these compounds are
derived from the methyl end of the fatty acyl chain following C–C
bond cleavage [7–9]. The majority of studies carried out to+ OH2
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Fig. 1. Generic mechanisms for cleavage of oxidized fatty acyl chains to yield HNE a
rearrangement of a C–C to C–O bond. The resulting carbonium ion is unstable, and hydr
radical. The dioxetane can rearrange by a 2-electron process resulting in cleavage of the
2nd hydroperoxide, probably before fragmentation occurs. (C) In the presence of transiti
rearrangement resulting in b-scission.elucidate the mechanisms used puriﬁed lipids, especially linoleic
acid and linoleate methyl ester, although g-linolenic and arachi-
donic acids were also found to be good sources of HNE. Over the
years, many different mechanisms have been proposed, with
either two or three O
2 additions required, and with several
possible sites of oxidation owing to the radical rearrangements
following hydrogen abstraction at bis-allylic sites. The chemical
mechanisms that lead to cleavage of a carbon–carbon bond in the
fatty acyl chain can be broadly classiﬁed into the following types:
reduction of the hydroperoxide to an alkoxy radical by Fe2þ
followed by b-scission; a Hock rearrangement of a hydroperoxide,
entailing an acidiﬁed hydroperoxide (–OH2
þ) acting as a leaving
group, and migration of a C–C to a C–O bond and cleavage; or
dioxetane formation and cleavage, especially via peroxycycliza-
tion reactions (Fig. 1).
The earliest suggestions for mechanisms for the formation
of HNE were based on the observations of hydroperoxyper-
oxides as intermediates (9/13-hydroperoxyoctadecadienoate
[HPODE] from methyl-linoleate (Fig. 2) or 11/15-hydroperox-
yeicosatetraenoate [HPETE] from methyl-arachidonate) and
enhanced HNE and oxo-nonanoic acid (ONA) formation in
the presence of transition metal ions, such as Fe2þ , which
are known to convert hydroperoxides to alkoxy radicals
[7,9,10]. A mechanism involving addition of three O2 via 13-
HPODE to form an epoxyhydroperoxide intermediate that
underwent a Hock cleavage was proposed by Pryor and Porter
[10], while Loidl-Stahlhofen et al. reported an Fe2þ-dependent
mechanism with a hydroxyhydroperoxy intermediate that
underwent b-scission [11]. This mechanism generated HNE
plus a vinylperoxy radical that readily converted to a known
product, ONA, and was considered feasible because an analo-
gous enzymatic route was discovered in plants, dependent onO
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C.M. Spickett / Redox Biology 1 (2013) 145–152 147lipoxygenase and a hydroperoxide lyase [12]. An alternative
mechanism reported a few years later involves cyclization of a
peroxy radical (9-PODE or 11-PETE) to form a 9,10-dioxetane
that could rearrange to cleave the chain [13]; interestingly,
this route requires the addition of only two O2. Further
support for a mechanism similar to hydrohydroperoxy frag-
mentation was presented by Schneider et al. [14], who found
that 9S-HPODE is cleaved following a Hock rearrangement to
yield 3Z-nonenal that is then oxidized further to 4-HPNE,
whereas 13S-HPODE forms an unstable dihydroperoxide that
undergoes Hock cleavage to give 4-HPNE directly. However,
more recently the same group have proposed that cross-chain
peroxyl radical addition and decomposition can occur, with
formation of dimeric or even trimeric oxidized fatty acyl
chains [15] and have obtained evidence for its occurrence in
tetralinoleoyl cardiolipin [16]. It is argued that this route
represents a competition with bis-allylic hydrogen abstrac-
tion, and therefore it seems most likely for linoleic acid, where
there is no bis-allylic site at the critical stage of the mechan-
ism. Finally, earlier this year evidence was presented for the
role of a diepoxycarbinyl radical that can interconvert
between 9-allyloxy and 13-allyloxy forms, and undergo b-
scission to either HNE and ONE/ ONA, or hexanal plus KODA/
HODA [17]. The structures of the several of these reactive
intermediates are shown in Fig. 2. In conclusion, sound
evidence has been obtained for several different routes from
linoleate and arachidonate to HNE plus ONE, and hexanal plusHODA, which incidentally shows that hexanal is not formed
only from o-3 fatty acids.Metabolism of 4-hydroxy-2-nonenal
In many tissues, HNE can be metabolized to less cytotoxic
compounds, which are also more water-soluble, facilitating their
excretion [18]. The use of tritiated HNE enabled early studies of
the metabolic pathways in several laboratories, and hepatocytes,
thymocytes and enterocytes from small intestine are known to be
particularly efﬁcient at metabolizing HNE [19]. An important
pathway for detoxiﬁcation of HNE involves conjugation to the
thiol group of the antioxidant glutathione by glutathione-S-
transferases, especially GSTA4–4 [20], which results in loss of
the a,b-unsaturation and formation of HNE-GSH adduct or its
lactone form. This can be reduced by aldose reductases to
1,4-dihydroxynonene-GSH, although the enzymes are also cap-
able of reducing free HNE to 1,4-dihydroxynonene. Alternatively,
aldehyde dehydrogenases (ALDH) are able to oxidize HNE to HNA,
either in free or conjugated form, and HNA may be hydroxylated
by cytochrome P450 4A to form 9-hydroxy-HNA. Studies
of rats in vivo have found that HNE metabolites in urine are most
commonly in the mercapturic acid form, with the major
component reported to be 1,4-dihydroxynonane-mercapturic acid
(DHN-MA) [21], and consequently an immunoassay for this
urinary metabolite has been developed [22]. The importance of
C.M. Spickett / Redox Biology 1 (2013) 145–152148aldehyde dehydrogenase and aldose reductase for metabolism of
HNE has been demonstrated in rat cardiac myocytes, using
[3H]HNE [23]. More recently studies of myocardial ischaemia
have shown that mitochondria contribute signiﬁcantly to HNE
metabolism by direct oxidation to HNA, rather than conjugation
to GSH; in ischaemia this reaction is inhibited and increased
formation of HNE-protein adducts occurs in the mitochondria.
The mitochondrial oxidation of HNE was found to be regulated
primarily by the NADþ/NADH ratio [24].Analysis of free 4-hydroxy-2-nonenal
In understanding the formation and biological roles of HNE, an
important aspect is its detection and measurement in tissues. There
are a variety of methods available for analysis of HNE (Fig. 3), but in
view of its reactivity a fundamental issue is whether to measure free
aldehyde, or adducts of HNE. Methods for detection and quantiﬁca-
tion of free HNE have been reviewed by Esterbauer et al. [2,25]. HNE
absorbs in the UV range (220–223 nm), and in protein-free samples
with levels of HNE in the micromolar range it can be detected directly
following separation from other aldehydes by HPLC. However, in
biological samples, more speciﬁc and sensitive detection can be
achieved by the use of aldehyde-reactive probes, of which 2,4-
dinitrophenylhydrazine (DNPH) and 1,3-cyclohexandione (CHD) have
been most used, but many others exist [26]. HPLC and use of
standards is still required to identify HNE within the complex
mixtures of alkanals, alkenals and modiﬁed alkenals that can occur,
as the probes per se do not distinguish between the aldehydes.
Alternatively, mass spectrometric analyses can be carried out, which
have the advantage that the mass to charge ratio and fragmentation
pattern can be used to identify the compound. GC–MS requires
derivatization of the sample, for example with pentaﬂuorobenzyl
(PFB) oxime followed by silylation, and the derivatized HNE can be
detected with negative chemical ionization and quantiﬁed by com-
parison with deuterated HNE as internal standard [27,28]. LCMS
approaches to detecting HNE have the advantage that derivatization
to obtain a volatile compound is not required, so the sample can beFree HNE
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Fig. 3. Overview of most common methods for detecanalyzed with minimal handling [29,30]. However, analysis of free
HNEmay have limited value: owing to its reactivity a large part of the
HNE formed may exist as adducts with other biomolecules, such as
proteins, DNA or aminophospholipids. The structures of HNE adducts
with amino acid residues, including Schiffs base formation with lysine
and Michael adducts with cysteine, histidine, lysine and arginine,
have been nicely described in several reviews [31–33]. Consequently,
many studies have focused on the detection of HNE adducts
with proteins, and the two main approaches available are immuno-
chemical techniques and mass spectrometric analysis. Although
Schiffs base adducts are generally regarded as more readily reversible
than Michael adducts, the latter can also be reversible, especially the
lysine-HNE Michael adduct [34,35]. It is important to bear this in
mind, as it can inﬂuence the adducts that are observed: for example,
it has been reported that HNE Michael adducts represent more than
99% of the protein modiﬁcations detected [36], and that His-Michael
adducts are most stable, although the most favourable reaction is
Michael addition to lysine [37]. Consequently, many studies include a
reduction step with borohydride, which stabilizes Schiffs bases and
some Michael adducts, prior to analysis.Analysis of 4-hydroxy-2-nonenal adducts by immunoassay
The development of antibodies speciﬁc for HNE bound to
proteins or other biomolecules has undoubtedly been extremely
useful in establishing the range of pathologies where HNE is
produced and showing its tissue distribution by immunohistochem-
istry. The earliest report of anti-HNE and anti-malondialdehyde
(MDA) antibodies is by Palinski et al. [38], although antisera
against other forms of modiﬁed LDL had been reported previously
[39]. Polyvalent and monoclonal antibodies were raised against
cyanoborohydride-reduced HNE-treated LDL, and it was reported
that the antibodies recognized a 4-HNE-lysine adduct on LDL and
other proteins, but were unreactive with native LDL [38,40]. In
subsequent work in Austria, antibodies were raised against a non-
reduced HNE-LDL adducts, and found that there was cross-reactivity
with HNE-albumin, and to a lesser extent, HNE-HDL [41,42]. A solidHNE-Protein Adducts
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antiserum, and competition assays with HNE-modiﬁed poly-(L-
amino acids) indicated that HNE-poly-(L-lysine) and (in decreasing
order of effectiveness) HNE-poly-(L-tyrosine), HNE-poly-(L-arginine),
and HNE-poly-(L-histidine) could be recognized. There was also
cross-reactivity with LDL modiﬁed with 2,4-heptadienal and hex-
anal, but not with MDA-LDL.
Polyclonal serum against HNE-treated keyhole limpet haemo-
cyanin (KLH) was produced by Uchida et al. [43], and this group
went on to use this immunogen to produce ﬁve monoclonal
antibodies with high speciﬁcity for HNE-histidine adducts on
GAPDH, of which HNEJ-2 was the most effective [44]. Further
monoclonal antibodies were produced by immunizing rabbits with
HNE-conjugated heptapeptide (Gly3–His–Gly3 amide) coupled to
KLH [45]. These antibodies showed no signiﬁcant cross-reactivity
with proteins treated with MDA, hexanal, 2-hexenal or 2-trans-
nonenal, but there was some reactivity towards proteins treated
with other hydroxyalkenals, namely 4-hydroxy-2-octenal and
4-hydroxy-2-decenal, as well as with HNE-cysteine and HNE-
lysine. It was therefore concluded that the epitope recognized was
the 2-CH3(CH2)n-5-hydroxytetrahydrofuran moiety, which is
formed by cyclization of the Michael adduct [45]. Essentially in
parallel, a series of monoclonal antibodies from mice were also
generated by Waeg et al. [46], using BSA and KLH treated with 4-
hydroxyalkenals. One of the clones, Ig4, was found to be highly
speciﬁc for HNE-histidine adducts, with little cross-reaction with
HNE-lys or HNE-cys, or with shorter hydroxyalkenals (e.g. 4-hydro-
xyhexanal). Later, a new monoclonal antibody with reactivity versus
a ﬂuorescent derivative of HNE with the e-amino group of lysine
was developed by conjugation of the hydroxyiminodihydropyrrole
(HIDP) to KLH [47]; HIDP is known to form in LDL following HNE
modiﬁcation. The monoclonal antibody bound both HIDP and 4-
oxo-nonenal readily, showed much lower reactivity against HNE-
adducts, and very little activity versus all other aldehydes. Another
group produced rabbit polyclonals with speciﬁcity for HNE adducts
of cysteine and DNPH-labelled HNE-SH adducts [48], which areuseful as DNPH is often used as a carbonyl-speciﬁc labelling reagent.
The ﬁrst antibody to a hydroxyalkenal cross-linked product was
prepared by Cohn et al. [49], who raised polyclonal antibodies to
HNE-cross-linked lysine residues (reduced Schiffs base and a
Michael addition) on glucose-6-phosphate dehydrogenase. Interest-
ingly, a mAb raised against the R-HNE-histidine adduct was found to
have sequence homology with anti-DNA autoantibodies detected in
systemic lupus erythematosus, and cross-reactivity with 4-oxo-2-
nonenal-treated DNA, thus showing dual speciﬁcity of some anti-
HNE antibodies [50].
There has been interest from the early stages in the develop-
ment of ELISAs as quantitative techniques for analyzing HNE-
protein adducts. In 1995, an ‘‘HNE-trapping ELISA’’ designed to
quantify free HNE by its reaction with protein coating the plate,
and HNE-His adducts were detected using mAbHNEJ-2 [51]. A
rapid competition ELISA for detecting pre-formed HNE-His
adducts on proteins was subsequently reported by the same
group, and used to detect immunoreactive components in rat
serum and urine [52]. More recently, a kit for detecting HNE-his
adducts in lysates of cultured cell subjected to slight or severe
oxidative stress has been developed [53], and shows good
sensitivity for cell samples although it requires reﬁnement for
use with plasma. An enzyme immunoassay for quantitative
analysis of the urinary HNE metabolite 1,4-dihydroxynonane-
mercapturic acid (DHN-MA) has also been reported, which uses
polyclonal serum raised against DHN-MA linked to KLH [22].
Many of the anti-HNE adduct antibodies developed were used
for immunocytochemistry and immunohistochemistry, and
demonstrated the occurrence of HNE-modiﬁed LDL and proteins
in inﬂammatory loci such as human atheromatous lesions
[38,45,47] or in oxidatively stressed mitochondria [49], cultured
cells [33], apoptotic hippocampal neurones [54], or ischaemic rat
heart [55]. There are also a number of more recent studies, for
example in neurodegenerative disease [56,57]. Anti-HNE antibo-
dies were used for western blotting of extracts of Alzheimers
disease brain, and HNE-adducts were found on a number of energy
metabolism proteins (e.g. malate dehydrogenase and enolase) as
well as Mn superoxide dismutase. The neuronal communication
protein dihydropyrimidinase-related protein 2 (DRP-2) also
showed increased HNE adducts in early Alzheimer’s disease
[58,59]. However, the exact sites of adduction were not identiﬁed
in these studies, limiting conﬁdence in the hypothesis that these
speciﬁc proteins were modiﬁed.Labelling approaches to detect 4-hydroxy-2-nonenal-protein
adducts
3H-labelled HNE has been used to determine the metabolic
fate of this lipid peroxidation product in tissues and animal
studies, as described above, and has allowed some basic assess-
ments of the cellular locations of protein-bound HNE [24]. An
alternative approach to identifying cellular targets of attack by
electrophilic lipid products is to use electrophilic compounds pre-
labelled with either biotin or a ﬂuorescent tag such as bodipy.
Cells or tissues are treated with the tagged compounds, which
allow the proteins covalently bound to the lipids to be identiﬁed
[26]. While initially used for phospholipids [60,61], a similar
approach for HNE involving click chemistry has been reported
for HNE [62]. Azido-tagged HNE or alkynyl-tagged HNE was
incubated with cultured colorectal cells to allow adduction to
target proteins, and after extraction biotin-triphenylphosphine or
the appropriate biotin label for click chemistry were added to
label the lipid covalently. While this is a smart and informative
protocol, unfortunately it cannot be translated to identify lipox-
idized proteins in vivo in humans, owing to the requirement for
C.M. Spickett / Redox Biology 1 (2013) 145–152150artiﬁcially labelled lipid in the tissue of interest. Ideally, it also
requires the use of mass spectrometry techniques to identify the
tagged protein.Analysis of 4-hydroxy-2-nonenal adducts by mass
spectrometry
While the use of HNE-speciﬁc antibodies in ELISAs and
immunostaining allows detection and quantitation of adducts,
there can be questions over the exact nature of adducts and the
protein modiﬁed. The most informative, though at the same time
the most challenging, method for characterizing HNE adducts is
undoubtedly mass spectrometry (MS). MALDI-TOF-MS is often
used for peptide mass ﬁngerprinting and adducts can be detected
by the increase in mass to charge ratio of the peptide compared to
the native form. MSMS allows sequencing of proteins and identi-
ﬁcation of the site of post-translational modiﬁcations, including
the formation of adducts by lipid peroxidation breakdown pro-
ducts (Fig. 4). Samples are usually reduced with dithiothreitol and
treated with iodoacetamide to block cysteines and prevent cross-
linking, before subjecting to digestion with MS grade trypsin. The
tryptic peptides are separated by (nano)LC and sequenced by
fragmentation in the mass spectrometer. The data acquired is
usually processed through a software programme called Mascot,
which matches it to in silico tryptic peptide data calculated using
proteomic databases, by a statistical process. The masses for HNE
modiﬁcations to the various amino acids, for example by Schiffs
base (138 Da) or Michael addition (156 Da) [32,63], can be added
to the search database as variable modiﬁcations. However, owing
to the statistical nature of the processing algorithm it is important
to check the MS data manually to conﬁrm the modiﬁcations. The
analysis is complicated further by the possibility of reduced
products (corresponding to addition of 2 Da) following treatment
of the samples with sodium borohydride or cyanoborohydride to
stabilize the adducts, or structural rearrangements, such as the
cyclization to a pyrrole form. MS methodologies have been used
both to investigate the reaction of HNE (or other aldehydes)
in vitro with individual proteins, and to identify HNE-modiﬁed
proteins in biological samples.
Liu et al. [64] conducted a thorough investigation of myoglobin
modiﬁcation by HNE and ONE adducts using LC-MSMS and
identiﬁed covalent adducts on several peptides, and this work
was expanded later to the reactions of other electrophilic oxida-
tion products of linoleic acid with b-lactoglobulin as a model
proteins; mass shifts for many the adducts were reported [35].
Formation of adducts between HNE and six histidine residues of
myoglobin, resulting in instability has also been reported [65].
Other examples of characterization of HNE modiﬁcations in
vitro include the detection of adducts at histidine, lysine and
arginine residues of cytochrome c [66], and histidine and cysteine
residues of creatine kinase analyzed by FT-ICR MS, which
correlated with decreased activity of the protein [67]. This is
similar to an earlier report on the loss of GAPDH activity
following treatment in vitro with HNE, which was linked to the
modiﬁcation of lysine, histidine and cysteine residues observed
by LC-MSMS, although the active site cys149 was found not to be
affected [68].
There have also been studies of HNE adduct formation in vivo.
MALDI-TOF-MS analysis has been used to show modiﬁcation of
erythrocyte catalase by HNE in systemic lupus erythematosus, but
the actual site of modiﬁcation was not reported [69]. In a rat
model of chronic alcoholic liver diseased Hsp90 was identiﬁed by
immunoblot with anti-HNE-antibody as a target of HNE, although
Cys572 was only identiﬁed as the site of adduction by treatment
of Hsp90 in vitro and LC/MS/MS [70]. Similar work in miceinvestigated modiﬁcation of proteins from obese adipose tissue,
except that carbonyl-containing proteins were enriched using
biotin hydrazide, and A-FABP (a cytoplasmic fatty acid carrier
protein) was studied further in vitro and found to be modiﬁed
HNE at Cys117 [71]. Enrichment approaches have also been used
by other groups to improve the yield of HNE-modiﬁed proteins in
analyses of biological sample. For example, biotin hydrazide and
avidin capture followed by LC/MS/MS found 24 modiﬁcations in
14 proteins from human plasma. However, many of the modiﬁca-
tions corresponded to direct oxidations of residues and only one
adduct of 4-HNE was observed on Apolipoprotein B-100 [72,73].
Better results were obtained using a combined protocol involving
peptide enrichment with an anti-HNE-antibody afﬁnity column,
mass spectrometry and de novo sequencing, which identiﬁed
HNE-adducts of several membrane proteins in healthy human red
blood cells [74]. A similar approach was applied with success to
healthy cardiac myocytes [75].
Targetted approaches to ﬁnding HNE-adducts are also begin-
ning to emerge as useful methodologies. Rauniyar et al. [36,76]
also reported the use of neutral loss scanning for m/z 138 or 156
with HNE-treated cytochrome c oxidase as a model protein, using
a neutral loss driven MS3 scan to sequence any peptides that
demonstrated these losses, and were able to identify a substantial
number of Michael adducts mainly of histidine but also lysine and
cysteine. The same group also obtained good results with solid
phase hydrazide enrichment and a combination of collision-
induced dissociation and electron capture dissociation to detect
HNE elimination (loss of m/z 156) as a signature tag, although this
was also carried out with a model protein, rather than in vivo
[77]. The value of neutral loss scanning for m/z 156 and 138 was
also demonstrated in blood samples to select speciﬁcally peptides
containing Michael adducts or Schiffs bases of HNE respectively;
HNE Michael adducts formed at lys497 and his494 of b-spectrin
were detected by this method [74]. An isotope-code tagging
protocol for quantitative analysis of HNE-modiﬁed peptides has
also been reported and applied to a complex mixture of digested
plasma proteins [78].Conclusion and future perspectives on 4-hydroxy-2-nonenal
Nearly 50 years on from the initial discovery of bioactives
4-hydroxyalkenal products, there is a large body of knowledge on
the chemistry and biochemistry of HNE. While questions do still
remain about the chemical mechanisms by which HNE is formed
during lipid peroxidation, several critical intermediates have been
isolated and identiﬁed, and it is clear that more than one pathway
exists. The local membrane and cellular environment during the
lipid peroxidation process, such as fatty acyl composition and pH,
most likely determine the ﬂux through the possible pathways.
Mass spectrometric analysis has been instrumental in under-
standing the intermediates and pathways during studies of lipid
peroxidation in vitro, and is now the main approach to identifying
sites of HNE modiﬁcation on proteins and characterizing the
structure of adducts both in vitro and in vivo. The MS technolo-
gies available for this purpose are continually improving, and will
underpin advancements in understanding of the functional con-
sequences of protein modiﬁcation by HNE (and other reactive
lipid peroxidation products). Increasing evidence is emerging for
the action of HNE in modulating protein activity and function, and
in redox regulation of cell signalling pathways, as has been
discussed recently in many publications and reviews [8,79–84].
The next objectives of research in this ﬁeld are likely to be a
molecular understanding of the role of HNE in physiological
signal regulation, and therapeutic strategies targetting formation
and effects of reactive aldehydes [85,86].
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